About
Alain Parthoens has more than twenty years of international experience in the food and life sciences businesses including marketing for Nestlé, business analysis for Kemira, product development and strategic planning for Monsanto and consultancy in R&D for pharmaceutical companies with PriceWaterhouseCoopers in London. Before he joined Vesalius Biocapital, Alain was an Investment Director at ING Corporate Investments in Belgium. Since 2001, he has been the lead investor for the private placement of Unibioscreen (oncology, EUR 19 m raised), MTI (stress resistant corn germplasm, EUR 14 m raised), OncoMethylome Sciences (cancer diagnostics, creation of the company, EUR 29 m raised in round A & B followed in June 2006 by a EUR 28 m IPO on Euronext), TiGenix (regenerative medicine, EUR 12 m raised, followed by EUR 16 m pre-IPO round and an IPO of EUR 40 m in March 2007) and most recently Bienca (food preservation, EUR 5 m raised). He was also actively involved in the private placement of Bi
Position in the VCSift Database
- • 7 investors at Vesalius Biocapital Partners are tracked.
- • 1,303 investors hold the Managing Partner role in VCSift. Alain Parthoens is one of them.
- • 371 investors are based in Brussels, Brussels Hoofdstedelijk Gewest, Belgium.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Brussels, Belgium
Contact Information
Find more investors like Alain
Search Investors